We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Cartridge-Based Antigen Testing System Delivers PCR Equivalent Performance at Half the Price

By HospiMedica International staff writers
Posted on 19 May 2023
Print article
Image: The first-in-class diagnostic platform technology will enable faster and more precise diagnosis (Photo courtesy of Burst Diagnostics)
Image: The first-in-class diagnostic platform technology will enable faster and more precise diagnosis (Photo courtesy of Burst Diagnostics)

A new first-in-class diagnostic platform technology that is transitioning from a working prototype to a commercial system is soon set to disrupt the point-of-care diagnostics industry.

Zymo Research (Irvine, CA, USA) has joined hands with Burst Diagnostics (Fort Collins, CO, USA) to create a pioneering diagnostic platform technology. This first-in-class diagnostic platform technology has the potential to deliver unmatched sensitivity and never-seen-before multiplexing abilities in antigen-based point-of-care testing. The platform is based on a novel microfluidic cartridge that is capable of miniaturizing and integrating all the traditional steps commonly carried out in a clinical lab environment (including washing and signal amplification) into a compact, sturdy, and electricity-free hand-held device.

The cartridge-based antigen testing system promises performance on par with PCR-based testing but at half the cost. The ELISA system bears a striking resemblance to a rapid antigen test but comes with an integrated high-sensitivity chemiluminescence reader. Burst plans to offer rapid immunoassays with fewer false negatives than standard rapid antigen tests used in point-of-care situations while also providing these results at lower costs than lab-based tests. Burst is planning further studies and is aiming to submit an application for authorization from the US Food and Drug Administration for its inaugural test and reader by the first quarter of 2024. The company's first offering is likely to be a multiplex test for COVID-19, influenza A and B, and RSV. Additionally, Burst is in the initial stages of developing tests for sexually transmitted infections and strep throat.

"The tests we are building are simple, convenient, and inexpensive like rapid antigen tests but capable of producing laboratory-quality data with the level of sensitivity and accuracy previously exclusive to central lab run tests," said Dr. Charles Henry, Founder and CEO of Burst Diagnostics.

"We have a radical new technology and with it, we will challenge the limitations associated with antigen tests as we know them," added Dr. Rose Nash, Chief Operating Officer and Scientist at Burst Diagnostics.

"The creation of this advanced and ultra-sensitive technology will transform the industry and significantly impact the healthcare sector. It will enable faster and more precise diagnosis and treatment of diseases," said Dr. Larry Jia, Founder and CEO of Zymo Research.

Related Links:
Zymo Research
Burst Diagnostics 

Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Digital X-Ray Flat Panel Detector
2121DXV
New
Patient Transfer Stretcher
TT-Patient Transfer Stretcher
New
Chair Scale
seca 954

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: New technology gives patients the power to heal chronic wounds using their own blood (Photo courtesy of RedDress)

POC Solution Creates In Vitro Blood Clots from Patient’s Own Whole Blood in Real-Time to Treat Post-Surgical Wounds

Blood clots are a natural mechanism of the body's healing process. However, for chronic wounds resulting from diabetes and other conditions, blood is unable to reach these areas, hampering the initiation... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.